Xavier Calvet
Centro de Investigación Biomédica en Red
Hospital de Sabadell
Barcelona
Spain
Name/email consistency: high
- What is the best first-line therapy for Helicobacter pylori infection?. Calvet, X. Nature Clinical Practice. Gastroenterology & Hepatology (2008)
- Helicobacter pylori infection: treatment options. Calvet, X. Digestion (2006)
- Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Calvet, X., Gallardo, O., Coronas, R., Casellas, F., Montserrat, A., Torrejón, A., Vergara, M., Campo, R., Brullet, E. Inflamm. Bowel Dis. (2006)
- What is potent acid inhibition, and how can it be achieved?. Calvet, X., Gomollón, F. Drugs (2005)
- Addition of a second endoscopic treatment following epinephrine injection improves outcome in high-risk bleeding ulcers. Calvet, X., Vergara, M., Brullet, E., Gisbert, J.P., Campo, R. Gastroenterology (2004)
- Diagnosis of Helicobacter pylori infection in dyspeptic patients by stool antigen detection usefulness of a new monoclonal enzyme immunoassay test. Calvet, X., Quesada, M., Sanfeliu, I., Salceda, F., Roselló, M., Montserrat, A., Brullet, E., Segura, F. Dig. Liver. Dis (2004)
- Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study. Calvet, X., Montserrat, A., Güell, M., Vergara, M., Gené, E. Eur. J. Gastroenterol. Hepatol (2004)
- Stool antigen for the diagnosis of Helicobacter pylori infection in cirrhosis: comparative usefulness of three different methods. Calvet, X., Quesada, M., Roselló, M., Salceda, F., Sanfeliu, I., Dalmau, B., Gil, M. Aliment. Pharmacol. Ther. (2003)
- Helicobacter pylori does not play a part in the dyspeptic complaints of rheumatology patients receiving long term treatment with non-steroidal anti-inflammatory drugs. Calvet, X., Gratacòs, J., Font, J., Larrosa, M., Sanfeliu, I., Roqué, M. Ann. Rheum. Dis. (2002)
- One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. Calvet, X., Ducons, J., Guardiola, J., Tito, L., Andreu, V., Bory, F., Guirao, R. Aliment. Pharmacol. Ther. (2002)
- Evaluation of Helicobacter pylori diagnostic methods in patients with liver cirrhosis. Calvet, X., Sanfeliu, I., Musulen, E., Mas, P., Dalmau, B., Gil, M., Bella, M.R., Campo, R., Brullet, E., Valero, C., Puig, J. Aliment. Pharmacol. Ther. (2002)
- Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment. Calvet, X., Garcia, N., Gené, E., Campo, R., Brullet, E., Sanfeliu, I. Aliment. Pharmacol. Ther. (2001)
- What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. Calvet, X., Gené, E., López, T., Gisbert, J.P. Aliment. Pharmacol. Ther. (2001)
- Helicobacter pylori is not a risk factor for hepatic encephalopathy. Calvet, X., Nogueras, C., Roqué, M., Sanfeliu, I. Dig. Liver. Dis (2001)
- Four-day, twice daily, quadruple therapy with amoxicillin, clarithromycin, tinidazole and omeprazole to cure Helicobacter pylori infection: a pilot study. Calvet, X., Titó, L., Comet, R., García, N., Campo, R., Brullet, E. Helicobacter (2000)
- A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Calvet, X., García, N., López, T., Gisbert, J.P., Gené, E., Roque, M. Aliment. Pharmacol. Ther. (2000)
- Validation of phone interview for follow-up in clinical trials on dyspepsia: evaluation of the Glasgow Dyspepsia Severity Score and a Likert-scale symptoms test. Calvet, X., Bustamante, E., Montserrat, A., Roqué, M., Campo, R., Gené, E., Brullet, E. Eur. J. Gastroenterol. Hepatol (2000)
- Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. Calvet, X., López-Lorente, M., Cubells, M., Barè, M., Gálvez, E., Molina, E. Aliment. Pharmacol. Ther. (1999)
